Psilocybin, the psychedelic component of magic mushrooms, can be an effective treatment for depression when delivered alongside supportive psychotherapy.
Overview: Psychedelic substances have been studied for their therapeutic potential for several decades. Psilocybin, a naturally occurring psychedelic compound found in magic mushrooms, has gained renewed interest in recent years due to its potential to treat various health conditions such as depression. Recent clinical trials have demonstrated the efficacy of psilocybin, when administered alongside supportive psychotherapy, in the treatment of depression. Research suggests that several factors contribute to the therapeutic effects of psilocybin, including the nature of the psychedelic experience itself, changes in the connectivity of certain brain networks, and neuroplasticity. Additionally, the participant's mindset and the therapeutic environment, known as “set and setting,” are also extremely important. Further research is needed to fully understand the therapeutic potential and long-term effects of psilocybin.
Magic mushrooms are a type of fungi that contain psilocybin, a naturally occurring psychedelic compound. When you consume magic mushrooms, the psilocybin is broken down by your body into a chemical called psilocin. Psilocin has a particular way of attaching itself to certain parts of your brain called 5-HT2A serotonin receptors.
By binding to these receptors, psilocin can cause changes in the activity of these brain areas, which can lead to the effects associated with psilocybin use. These typically include enhancement of emotions, profound changes in perception and thinking patterns, and alterations in how an individual perceives and experiences themselves.
Psilocybin was researched years ago, particularly in the 1950s and 1960s when there was a significant amount of scientific interest in psychedelic substances. However, the introduction of the Controlled Substances Act in 1970 placed all classic psychedelics, including psilocybin, in Schedule 1, effectively ending most psychedelic research for several decades.
In recent years, there has been a renewed interest in the therapeutic potential of psilocybin and other psychedelic compounds, leading to a second wave of scientific exploration. A new generation of psychedelic researchers around the world are investigating the potential of these medicines to treat various health conditions such as end-of-life anxiety, post-traumatic stress disorder, substance use disorders, and chronic pain.
A pivotal moment in the modern era of psychedelic research occurred in 2006 when researchers at Johns Hopkins University published an important study on the safety and enduring positive effects of a single dose of psilocybin. The study found that psilocybin reliably induced “mystical-type experiences,” characterized in part by a sense of transcending the boundaries of time and space, and feelings of connectedness and unity with the universe.
67% of the participants in this study rated their psilocybin experience to be among the top five most meaningful experiences of their lives.
The study helped catalyze the revival of psychedelic research, leading to the launch of Johns Hopkins' Center for Psychedelic and Consciousness Research, which explores the effects of psychedelics on brain function and mood in both healthy individuals and those with psychiatric disorders.
Recent clinical trials have demonstrated the efficacy of psilocybin, when administered alongside supportive psychotherapy, in the treatment of depression.
In recent years, research on the therapeutic potential of psilocybin has gained momentum. Since Johns Hopkins University's 2006 study, its researchers have continued to publish promising research. This includes a study in 2016 that demonstrated that psilocybin-assisted psychotherapy reduced symptoms of depression and anxiety in patients with life-threatening cancer diagnoses.
Imperial College London also launched their own Psychedelic Research Center in 2019 and has conducted promising research showing psilocybin’s antidepressant effects, including the first-ever double-blind, randomized, controlled trial comparing the therapeutic effects of psilocybin and the established antidepressant medication escitalopram (Lexapro/Cipralex).
While the primary outcome measure of this study, the QIDS-SR-16 depression scale, did not show a statistically significant difference between psilocybin and escitalopram, psilocybin did produce greater reductions in depression according to the four depression rating scales used in the study.
In addition, psilocybin outperformed escitalopram in all secondary outcomes, including improvements in well-being scores, and reductions in anxiety, suicidal ideation, anhedonia, and sexual dysfunction. However, it's important to note that these results were not adjusted for the possibility of chance findings when multiple comparisons are made.
In 2020, the team at Johns Hopkins published a randomized trial showing psilocybin's effectiveness in treating Major Depressive Disorder (MDD). The trial demonstrated a strong and fast-acting antidepressant effect that was durable for at least 12 months, producing a therapeutic effect approximately four times larger than traditional antidepressants.
Additionally, biotech company Compass Pathways published positive results from their largest peer-reviewed psilocybin therapy clinical trial to date. The study investigated the efficacy of their proprietary psilocybin formulation, COMP360, for treatment-resistant depression and found that 25 mg of psilocybin, administered with psychological support, produced statistically significant reductions in depression compared to placebo.
Importantly, there were some serious adverse events among participants in this study, the direct cause of which should be investigated by future research. Nevertheless, Compass Pathways plans to move forward with their Phase 3 program involving over 900 participants across 14 countries.
In another study, researchers at the University of Zurich found that a single, moderate dose of psilocybin significantly reduced depressive symptoms compared to a placebo condition for at least two weeks, with 54% of participants in remission at the end of treatment.
Research suggests that several factors may contribute to the therapeutic effects of psilocybin, including the nature of the psychedelic experience itself, changes in the connectivity of certain brain networks, and changes in the structure and function of the brain in response to the psychedelic experience known, also known as neuroplasticity.
However, the participants' mindset and the environment in which psychedelic-assisted psychotherapy takes place, known as “set and setting,” are also extremely important. The participant's mindset can influence the quality and nature of their experience, while the therapeutic environment can help ensure a positive and safe experience, and maximize the healing potential.
This is why controlled therapeutic contexts are typically used in psychedelic-assisted psychotherapy. These contexts involve carefully designed safety protocols and supportive therapy settings that help patients prepare for, navigate, and integrate their psilocybin experiences.
In the lead-up to the psilocybin experience, patients typically have several hours of preparatory therapy sessions. The preparatory therapy sessions that take place before the psilocybin experience can help participants develop a positive mindset and attitude toward their upcoming psychedelic experience.
These sessions are typically designed to build trust, establish rapport, and foster a sense of safety and support between the patient and therapist. This can help the participant feel more comfortable and secure, which may allow them to more fully engage in the experience and work through any issues that may arise.
During these preparatory sessions, the therapist may also help the participant set intentions for their psilocybin experience and discuss any fears or concerns they may have. This can help the participant feel more prepared and confident going into the experience, which may contribute to a more positive mindset and overall experience.
During the psilocybin session, patients lay on a couch wearing eye shades and headphones playing a carefully curated music playlist designed to ease tension and promote a healing experience. A co-therapy team is present to offer reassurance and encouragement as needed.
After the psilocybin session, patients have integrative therapy sessions to help them consolidate meaningful insights and integrate fresh perspectives into their lives. Integrative therapy sessions also help patients to make sense of anything that may have been confusing about their psychedelic experience.
It is important to understand that the therapeutic effects of psilocybin are not solely due to the drug itself. The controlled therapeutic context is a crucial element in ensuring a positive and safe experience, and in maximizing the potential for positive outcomes.
By creating a safe and supportive environment, patients may be better able to surrender to the experience and confront any difficult emotions or memories that may arise during the psychedelic experience.
As in an experience with synthetic psilocybin in the context of psychedelic-assisted psychotherapy, mindset and environment also greatly influence the nature and quality of an experience with psilocybin mushrooms outside of a clinical context.
When psilocybin mushrooms are used to treat depression outside of a clinical context, the mindset and environment may not be as carefully curated as in a therapeutic setting. This can lead to unpredictable experiences, both positive and negative, as the effects of the psilocybin can be influenced by a variety of factors such as the participant's mood, expectations, and surroundings.
However, it is recommended to intentionally create a safe and supportive environment for psilocybin mushroom experiences, such as being with trusted friends in a comfortable and familiar setting. This can help the user feel more at ease and open to the experience, potentially leading to a more positive outcome.
While the context may differ, the importance of mindset and environment in shaping the experience remains significant in both cases.
The legality of psilocybin mushrooms varies greatly depending on the country and even the region within a country. In some places, they are illegal and classified as a Schedule I drug, while in others they may be decriminalized or even legal for medical or research purposes. It is important to understand and adhere to local laws and regulations regarding the use of psilocybin mushrooms.
In conclusion, psilocybin has shown promising results in treating depression in recent clinical trials. While these findings are encouraging, it's important to note that the studies conducted to date have limitations, and further research is needed to fully understand the safety and efficacy of psilocybin for depression. Nonetheless, the therapeutic promise of psilocybin offers a glimmer of hope for those suffering from depression.
Content from the community